COVID-19有创通气患者的通气管理与临床结局(PRoVENT-COVID):一项全国性、多中心、观察性队列研究
PRoVENT-COVID是一项在荷兰18个ICU开展的全国性、多中心、回顾性观察性研究,纳入2020年3月1日至4月1日国家疫情第一个月内因COVID-19接受有创通气的连续成人患者553例。难治性低氧的辅助治疗中,俯卧位在通气前4天最常用(530例中283例,53%)。28天无呼吸机天数的中位数为0(IQR 0–15),530例中186例(35%)在28天内死亡。28天死亡率的预测因素包括性别、年龄、潮气量、呼吸系统顺应性、动脉pH和开始有创通气第一天的心率。
要点
- 通气前4天内,俯卧位是难治性低氧最常用的辅助治疗(530例中283例,53%)。
- 28天无呼吸机天数中位数为0(IQR 0–15),530例中186例(35%)在28天内死亡。
- 28天死亡率的预测因素包括性别、年龄、潮气量、呼吸系统顺应性、动脉pH和开始有创通气第一天的心率。
适用人群与场景
- 纳入标准:年龄至少18岁,在荷兰参与研究的ICU中因COVID-19接受有创通气,且处于荷兰国家疫情第一个月(2020年3月1日至4月1日)内的连续患者。
- 场景:18个ICU的成人有创通气患者;排除标准原文未提及。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:全国性、多中心、回顾性观察性队列研究,在荷兰18个ICU开展,纳入553例成人COVID-19有创通气患者。
- 难治性低氧的辅助治疗:俯卧位在通气前4天最常用,530例中283例(53%)。
- 患者中心结局:28天无呼吸机天数中位数0(IQR 0–15);530例中186例(35%)在28天内死亡。
- 28天死亡率的预测因素:性别、年龄、潮气量、呼吸系统顺应性、动脉pH、开始有创通气第一天的心率。
证据类型、等级与局限
- 证据类型:观察性队列研究(全国性、多中心、回顾性)。
- 证据等级或推荐强度:原文未提及。
- 局限:回顾性设计、观察性研究、单国家、仅纳入疫情第一个月患者;原文指出研究结果可为未来试验提供假设和样本量计算基础,并有助于解释其他通气实践与结局研究。
对床旁实践的改变
- 原文提示:在COVID-19有创通气患者中,低潮气量和低驱动压的肺保护性通气被广泛采用,俯卧位常用于难治性低氧;PEEP虽变异大但呼吸系统顺应性普遍低,提示PEEP设置需个体化。
- 原文未提及适用与不适用人群的进一步限定;常见陷阱原文未提及。
指南或共识出处
- PRoVENT-COVID研究,注册号ClinicalTrials.gov NCT04346342;发表于Lancet Respir Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Little is known about the practice of ventilation management in patients with COVID-19. We aimed to describe the practice of ventilation management and to establish outcomes in invasively ventilated patients with COVID-19 in a single country during the first month of the outbreak.
METHODS: PRoVENT-COVID is a national, multicentre, retrospective observational study done at 18 intensive care units (ICUs) in the Netherlands. Consecutive patients aged at least 18 years were eligible for participation if they had received invasive ventilation for COVID-19 at a participating ICU during the first month of the national outbreak in the Netherlands. The primary outcome was a combination of ventilator variables and parameters over the first 4 calendar days of ventilation: tidal volume, positive end-expiratory pressure (PEEP), respiratory system compliance, and driving pressure. Secondary outcomes included the use of adjunctive treatments for refractory hypoxaemia and ICU complications. Patient-centred outcomes were ventilator-free days at day 28, duration of ventilation, duration of ICU and hospital stay, and mortality. PRoVENT-COVID is registered at ClinicalTrials.gov (NCT04346342).
FINDINGS: Between March 1 and April 1, 2020, 553 patients were included in the study. Median tidal volume was 6·3 mL/kg predicted bodyweight (IQR 5·7-7·1), PEEP was 14·0 cm H2O (IQR 11·0-15·0), and driving pressure was 14·0 cm H2O (11·2-16·0). Median respiratory system compliance was 31·9 mL/cm H2O (26·0-39·9). Of the adjunctive treatments for refractory hypoxaemia, prone positioning was most often used in the first 4 days of ventilation (283 [53%] of 530 patients). The median number of ventilator-free days at day 28 was 0 (IQR 0-15); 186 (35%) of 530 patients had died by day 28. Predictors of 28-day mortality were gender, age, tidal volume, respiratory system compliance, arterial pH, and heart rate on the first day of invasive ventilation.
INTERPRETATION: In patients with COVID-19 who were invasively ventilated during the first month of the outbreak in the Netherlands, lung-protective ventilation with low tidal volume and low driving pressure was broadly applied and prone positioning was often used. The applied PEEP varied widely, despite an invariably low respiratory system compliance. The findings of this national study provide a basis for new hypotheses and sample size calculations for future trials of invasive ventilation for COVID-19. These data could also help in the interpretation of findings from other studies of ventilation practice and outcomes in invasively ventilated patients with COVID-19.
FUNDING: Amsterdam University Medical Centers, location Academic Medical Center.
参考来源
- Botta M, Tsonas AM, Pillay J, et al. Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study. Lancet Respir Med. 2020. PMID: 33169671. doi:10.1016/S2213-2600(20)30459-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。